Baxter International (BAX)
Health Care · Medical Devices and Supplies · NYSE
Baxter International is a leading medical technology company delivering critical life-sustaining therapies for patients with complex medical conditions in hospitals and at home.
What Baxter International does
Baxter International is a global medical technology company that provides a broad portfolio of essential healthcare products. Its offerings include hospital and renal care solutions, such as dialysis therapies, intravenous (IV) solutions, infusion systems, and specialized surgical and pharmaceutical products. The company focuses on addressing critical care needs in hospitals, clinics, and home settings.
Themes: renal care / dialysis, hospital solutions, infusion therapy, surgical technology, home healthcare
Fundamentals
- Price$23.90 as of 2026-10-08 close
- Market cap$12.4B as of 2026-07-23 (share count; price 2026-10-08)
- 1-year return+5.1% 2025-10-08 close $22.75 → 2026-10-08 close $23.90
- P/En/a negative earnings
- Net margin-8.5% FY2025, SEC XBRL
- Gross margin+30.1% FY2025, SEC XBRL
- ROE-15.7% FY2025, SEC XBRL
- Debt / equity1.52 as of 2026-09-03
- Revenue growth (YoY)+5.4% as of 2026-09-03
- Revenue CAGR (3y)+3.8% SEC XBRL
- Beta0.94 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.2%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
How BAX compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 10% 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BAX is not currently in any published Top 10 list. Its scores are below.
Top 10 score
39.0 #1218 of 1,379 scored · #136 of 151 in Health Care
Valuation 72nd (price to book 2) and trend 62nd (trading above its 200-day average); weakest is profitability (11th, return on equity -15.7%, operating margin -2.7%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, BAX's dividend exceeded at least one reported measure of what it earned or generated (free-cash-flow payout 105%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payout105% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Baxter International looks technically
Baxter International (BAX) is trading 14.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It made a new 20-day low about 15 trading days ago. It is 20.3% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 14.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +14.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.28 | $25.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.91 | $20.91 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 24.3. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal | 61 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($22.56 to $24.60) — its "stochastic" reading is 66 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 65.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $30.00 | $30.00 |
|---|---|---|
| From the 52-week high | it is 20.3% below its 52-week high (its highest price of the past year) | -20.3% |
| Above the 52-week low | it is 51.9% above its 52-week low (its lowest price of the past year) | +51.9% |
| Below the 52-week high | it is 20.3% below its highest point of the past year | 20.3% |
| Since a 20-day breakout | it made a new 20-day low about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 47 trading days ago | 47 sessions |
| All-time high | its highest closing price on record is $95.19 (set on 2020-04-20) | $95.19 |
| Given back of the 52-week move | over the past year its closes ranged ($15.80 to $28.35), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.19 to $20.59. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 35.5% |
| From the all-time high | it is 74.9% below its all-time high | -74.9% |
| Nearest price level | it is trading 1.2% above a support level at $23.61 — a price it turned at three times since 2025-10-20, most recently on 2026-07-17. Since 2024-10-08 it has 8 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.2% |
| All-time low | its lowest closing price on record is $9.88 (set on 2003-04-01) | $9.88 |
| Above the all-time low | it is 142.0% above its all-time low | +142.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7124 between its high and its low — about 3.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7124 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.83 and $24.39 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.83 – $23.61 – $24.39 |
| Typical daily range (% of price) | its price moves about 3.0% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.0% |
| Stretch from the 200-day average | it is trading 4.2 daily ranges above its 200-day average price (14.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.17× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.3% since the prior reading | -0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 2.8% gap down opened on 2026-08-20 has been "filled" 34 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 34 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -1.89% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.9 percentage points (the stock lost 3.9% while the market gained 1.0%) | -4.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.9 percentage points (the stock gained 8.7% while the market gained 3.8%) | +4.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 26.1 percentage points (the stock gained 43.5% while the market gained 17.5%) | +26.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 9.9 percentage points (the stock gained 5.1% while the market gained 15.0%) | -9.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.9% of the share price. | -3.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $20.84 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +14.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $25.31 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -5.6% |
Price levels it has turned at before
BAX last closed at $23.90 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.61 | Support | 1.2% below the last close | turned there three times · 2025-10-20 to 2026-07-17 |
| $24.48 | Resistance | 2.4% above the last close | turned there four times · 2025-08-29 to 2026-09-23 |
| $22.48 | Support | 5.9% below the last close | turned there twice · 2026-02-11 to 2026-09-21 |
| $21.39 | Support | 10.5% below the last close | turned there six times · 2025-08-01 to 2026-07-23 |
| $28.48 | Resistance | 19.1% above the last close | turned there twice · 2024-12-19 to 2024-12-30 |
| $29.28 | Resistance | 22.5% above the last close | turned there three times · 2025-06-03 to 2025-07-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $24.30.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 2 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.69 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$28.64 range $23.00 – $40.00; median $28.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BAX
- Consensus EPS estimate$0.5189 next reporting period, as of 2026-10-06
- Estimate change, 30 days$0.00 (0.0%) from $0.5189, on 2026-09-01, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant leverage and reliance on debt obligations","Operational and financial performance variability impacting net margins","Foreign currency exchange rate fluctuations affecting international operations"]
What changed in the latest 10-Q
AI-assisted comparison of BAX's 10-Q filed 2026-07-30 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-30) states the new operating model was implemented in the second quarter of 2026, whereas the older filing (2026-04-30) described the operating model as continuing to evolve without a noted implementation.
- Newer filing (2026-07-30) adds disclosure that the company changed its reportable segments from three segments (Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals) to two segments (Medical Products & Therapies and Healthcare Systems & Technologies), with the former Pharmaceuticals segment now reported within the Infusion Therapies & Platforms division of the Medical Products & Therapies segment.
- Newer filing (2026-07-30) adds that sales of products and services provided directly through certain manufacturing facilities related to Infusion Therapies & Platforms that were previously reported in Other are now reported in the Infusion Therapies & Platforms division.
- Newer filing (2026-07-30) adds that the company updated its approach to corporate cost allocations so that certain shared corporate expenses now remain unallocated rather than being fully allocated to segments, and that prior period segment disclosures have been recast.
- Newer filing (2026-07-30) adds reference to Note 16 for additional information on the segment change.
- Newer filing (2026-07-30) adds that no Novum LVP estimate adjustments were recorded in the second quarter of 2026.
- Newer filing (2026-07-30) adds that tariff refunds of approximately $75 million were recorded to costs of goods sold in the second quarter of 2026, including $65 million in prepaid expenses and other current assets, for probable receipt of amounts eligible for refund in the first and second phases of the process.
- Newer filing (2026-07-30) adds that the company does not expect any additional tariff refund amounts to be material to its condensed consolidated financial statements.
- Newer filing (2026-07-30) adds that the company expects results to continue to be adversely impacted by recently announced Section 301 tariffs that have been imposed following the judicial review of certain tariffs, in addition to Section 122 duties.
- Removed:
- Older filing (2026-04-30) stated no asset for tariff refunds had been recorded as of March 31, 2026, which is removed in the newer filing.
- Older filing (2026-04-30) included a statement that inflation and general macroeconomic factors have caused certain customers to reduce or delay orders and could cause them to do so in the future with a material adverse impact on sales and results of operations; this statement is not present in the newer filing extract.
- Older filing (2026-04-30) included a sentence referring readers to Item 1A, Risk Factors in the Annual Report for further discussion, which is not present in the newer filing extract.
- Older filing (2026-04-30) described the company as continuing to evolve its operating model, which is replaced in the newer filing by a statement that the new operating model was implemented in the second quarter of 2026.
- Reworded:
- Newer filing (2026-07-30) changes 'our former Kidney Care segment' to 'our former Kidney Care business' in the first paragraph of the completed strategic action discussion.
- Newer filing (2026-07-30) changes 'the timing of the release of the ship and installation hold' to 'the timing of the release of the shipment and installation hold' in the Novum LVP discussion.
- Newer filing (2026-07-30) changes 'are developing additional corrections related to these recalls' to 'have identified additional corrections to address these recalls, and are in the early stages of verification testing' in the Novum LVP discussion.
- Newer filing (2026-07-30) changes 'which could have a material adverse impact on our profitability and results of operations' to 'which could' at the end of the inflation and manufacturing costs discussion, with the sentence appearing truncated in the newer extract.
- Newer filing (2026-07-30) changes 'including the conflict in Iran' to 'including the ongoing conflict in Iran' in the geopolitical events discussion and again later in the same paragraph.
- Newer filing (2026-07-30) changes the tariff discussion from describing submitted refund requests and no recorded asset in the first quarter to recording $75 million of tariff refunds in the second quarter.
- Notes:
- The newer filing extract ends mid-sentence ('which could...'), and the older filing extract ends mid-sentence ('Net income (loss) attributable to Baxter stockholders f...'), so the comparison is limited to the portions of the MD&A provided.
Risk Factors
- Added:
- Newer filing (2026-07-30) added Exhibit 3.1 'Amendment to Amended and Restated Certificate of Incorporation of Baxter International Inc.' referencing a Form 8-K filed May 8, 2026.
- Newer filing (2026-07-30) added Exhibit 3.2 'Amended and Restated Bylaws of Baxter International Inc.' referencing a Form 8-K filed May 8, 2026.
- Newer filing (2026-07-30) added Exhibit 10.1 'Baxter International Inc. Executive Severance and Change in Control Plan' referencing a Form 8-K filed May 8, 2026.
- Newer filing (2026-07-30) added Exhibit 10.2 'Amendment to Andrew Hider Offer Letter, dated May 7, 2026' referencing a Form 8-K filed May 8, 2026.
- Newer filing (2026-07-30) added Exhibit 10.3 'Baxter International Inc. Second Amended and Restated 2021 Incentive Plan' referencing a Form 8-K filed May 8, 2026.
- Reworded:
- Newer filing (2026-07-30) states 'During the second quarter of 2026, we did not repurchase any shares' whereas older filing (2026-04-30) stated 'During the first quarter of 2026, we did not repurchase any shares' in Item 2.
- Newer filing (2026-07-30) states share repurchase balance 'as of June 30, 2026' whereas older filing (2026-04-30) stated 'as of March 31, 2026' in Item 2.
- Newer filing (2026-07-30) signature date is 'July 30, 2026' whereas older filing (2026-04-30) signature date is 'April 30, 2026'.
- Newer filing (2026-07-30) Item 2 ends at page 48 whereas older filing (2026-04-30) Item 5 ends at page 46, reflecting pagination differences.
- Notes:
- The provided texts include Items 1A, 2, 5, 6, and signature pages rather than only the Risk Factors section; the Risk Factors language itself is identical in both filings.
- Pagination differences are noted but not treated as substantive text changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for BAX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 7 matched disclosures for BAX from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding BAX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 158,927,445
- Reported value $3,388,533,466
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about BAX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
BAX had 23,227,313 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
BAX had 4.49% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.48 days to cover at the same settlement.
- Reported short interest (shares) 23,227,313
- Short interest (% of shares outstanding) 4.49%
- Prior settlement (shares) 23,293,667
- Reported change -0.28%
- Days to cover (reported) 4.48
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fresenius Medical Care (FMS)
- Becton Dickinson (BDX)
- Medtronic (MDT)
- B. Braun Melsungen
- DaVita (DVA)
- ICU Medical (ICUI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BAX vs…
Frequently asked questions
What does Baxter International (BAX) do?
Baxter International is a global medical technology company that provides a broad portfolio of essential healthcare products. Its offerings include hospital and renal care solutions, such as dialysis therapies, intravenous (IV) solutions, infusion systems, and specialized surgical and pharmaceutical products. The company focuses on addressing critical care needs in hospitals, clinics, and home settings.
What sector is Baxter International (BAX) in?
Baxter International (BAX) is classified in the Health Care sector. Its industry is Medical Devices and Supplies. It trades on NYSE.
Does BAX pay a dividend?
Yes — Baxter International (BAX) pays a dividend, with an indicated yield of about 0.18% and 1-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Baxter International's (BAX) competitors?
Notable peers of Baxter International (BAX) include Fresenius Medical Care, Becton Dickinson, Medtronic, B. Braun Melsungen and DaVita. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in BAX?
Yes — we hold 7 matched STOCK Act disclosures for BAX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Baxter International (BAX) overbought or oversold right now?
Baxter International (BAX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BAX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.